Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
28 Novembro 2023 - 10:13PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”)
announced today that it has priced an offering of $2.5 billion
aggregate principal amount (the “Offering”) of the following
notes:
- $1.0 billion aggregate principal amount of its 5.000% senior
notes due 2026 (the “2026 notes”), at the issue price of 99.931% of
their principal amount;
- $1.0 billion aggregate principal amount of its 5.000% senior
notes due 2029 (the “2029 notes”), at the issue price of 99.772% of
their principal amount; and
- $500 million aggregate principal amount of its 5.200% senior
notes due 2034 (the “2034 notes” and, together with the 2026 notes
and the 2029 notes, the “notes”), at the issue price of 99.846% of
their principal amount.
The Offering is expected to close on or about December 5, 2023,
subject to the satisfaction of customary closing conditions. The
notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use the net proceeds from the sale of
the notes for general corporate purposes, which may include the
acquisition of companies or businesses, repayment and refinancing
of debt, working capital and capital expenditures or the repurchase
of its outstanding equity securities or it may temporarily invest
the net proceeds in short-term, liquid investments until they are
used for their ultimate purpose.
The joint book-running managers for the Offering are BofA
Securities, Inc., Morgan Stanley & Co. LLC, US Bancorp
Investments, Inc. and Wells Fargo Securities, LLC.
The Offering is being made pursuant to an effective registration
statement on Form S-3 filed with the U.S. Securities and Exchange
Commission (the “SEC”). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the Offering and the other
documents that Thermo Fisher has filed with the SEC for more
complete information about Thermo Fisher and the Offering. These
documents are available at no charge by visiting EDGAR on the SEC
website at www.sec.gov. Alternatively, Thermo Fisher, the
underwriters or any dealer participating in the Offering will
arrange to send you the prospectus if you request it by calling
BofA Securities, Inc. toll-free at 1-800-294-1322, Morgan Stanley
& Co. LLC toll-free at 1-866-718-1649, U.S. Bancorp
Investments, Inc. toll-free at 1-877-558-2607 or Wells Fargo
Securities, LLC toll-free at 1-800-645-3751.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue over $40 billion. Our Mission is to
enable our customers to make the world healthier, cleaner and
safer. Whether our customers are accelerating life sciences
research, solving complex analytical challenges, increasing
productivity in their laboratories, improving patient health
through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about timing and
completion of the offering of the notes and Thermo Fisher’s
intended use of proceeds. These statements involve a number of
risks and uncertainties that could cause actual results to differ
materially from currently anticipated results, including risks and
uncertainties relating to capital markets conditions and completion
of the Offering. Additional important factors and information
regarding Thermo Fisher’s business that could cause actual results
to differ materially from those indicated by such forward-looking
statements are set forth in the “Risk Factors” section of the
prospectus dated February 25, 2022 and the preliminary prospectus
supplement dated November 28, 2023 related to the Offering and in
Part 1, Item 1A. “Risk Factors” of Thermo Fisher’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2022 and the other
documents incorporated by reference into the prospectus and
prospectus supplement, which are on file with the SEC and available
in the “Investors” section of our website under the heading “SEC
Filings.” While we may elect to update forward-looking statements
at some point in the future, we specifically disclaim any
obligation to do so, even if circumstances change and, therefore,
you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231128791585/en/
Media Contact Information: Sandy Pound Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information: Rafael Tejada Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Thermo Fisher Scientific (NYSE:TMO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024